Taken together, our findings have shown that cIAP2 expression is involved in HBV-induced sorafenib resistance in liver cancer, and that the inhibition of HBV replication and cIAP2 upregulation Akt pathway could partially restore cancer cell sensitivity to sorafenib. This evidence concerns the gene AKT1 and liver cancer.